Skip to main content

Table 1 Demographics and clinical pathological features of LiqBreasTrack-enrolled patients

From: Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Characteristics N (%)
Age, years (range) 56.8 (39.4–83.5)
ECOG Performance Status ≤2 22 (100)
IHC molecular markers
Primary tumor tissues 22
  ER+ and/or PgR+ 15 (68.2)
  ER- and/or PgR- 7 (31.8)
  HER2 1+/SISH or FISH+ 3 (13.6)
  HER2 2+/SISH or FISH+ 2 (9.1)
  HER2 3+ 17 (77.3)
Metastatic tumor tissues 9
  ER+ and/or PgR+ 6 (66.7)
  ER- and/or PgR- 3 (33.3)
  HER2 1+/SISH or FISH+ 1 (11.1)
  HER2 2+/SISH or FISH+ 3 (33.3)
  HER2 3+ 5 (55.6)
Previous lines of therapy
 1 14 (63.6)
 2 7 (31.8)
 3 1 (4.5)
Pertuzumab as first line treatment
  Yes 9 (40.9)
  No 13 (59.1)
Dominant Metastatic sites
 Liver 3 (13.6)
 Lung 3 (13.6)
 Bone 5 (22.7)
 Soft tissues 7 (31.9)
 Brain 4 (18.2)
Number of metastatic sites per patient
 1 8 (36.6)
 2 9 (40.9)
 ≥ 3 5 (22.7)
  1. Previous therapy lines included: Lapatinib plus Capecitabine, Trastuzumab plus Vinorelbine, Trastuzumab plus Carboplatin
  2. IHC Immunoistochemistry, ER Estrogen receptor, PgR Progesterone receptor, SISH/FISH Silver in situ hybridization/Fluorescent in situ hybridization